Emerging Markets Earnings Roundup: Novartis, Amgen (Part 2)
This article was originally published in PharmAsia News
Executive Summary
Novartis executives trumpeted robust growth across most emerging markets, while cautioning a slowdown in China due to the industry-wide compliance probe. For Amgen, a play to expand internationally is said to be paying off though questions remain about its plans for Japan.